Tominaga K, Shinkai T, Saijo N, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Nakajima T
Jpn J Clin Oncol. 1984 Dec;14(4):659-65.
Sister chromatid exchanges (SCE) frequency in cultured lymphocytes from seven patients with lung cancer receiving cis-Diamminedichloroplatinum(II) (Pt(II] for chemotherapy was studied. Significantly increased SCE frequency was observed in all the patients, six of whom received intravenous infusion of Pt(II) and one of whom received the agent as an intrapleural infusion. In addition, a dose-dependent increase in the frequency of SCE was observed in lymphocytes from healthy subjects upon exposure to Pt(II) in vitro. The results of the present study revealed that Pt(II) is a potent inducer of SCE in human lymphocytes in vivo and in vitro. It thus appears that follow-up study of the long-term survivors who have been treated with this agent for cancer is necessary because of the possible occurrence of secondary neoplasms.
研究了7例接受顺二氯二氨铂（Pt(II)）化疗的肺癌患者培养淋巴细胞中的姐妹染色单体交换（SCE）频率。所有患者的SCE频率均显著增加，其中6例接受了Pt(II)静脉输注，1例接受了胸膜内输注。此外，体外暴露于Pt(II)的健康受试者淋巴细胞中观察到SCE频率呈剂量依赖性增加。本研究结果表明，Pt(II)在体内和体外都是人淋巴细胞中SCE的有效诱导剂。因此，由于可能发生继发性肿瘤，对接受该药物治疗癌症的长期幸存者进行随访研究似乎是必要的。
